Nancy E. Davidson, MD | Authors

Articles

Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why?

June 19, 2019

In this article, we provide a case-based expert opinion on the duration of extended adjuvant endocrine therapy, use of biomarkers in guiding this decision, and toxicities to be considered when recommending this treatment.

An Interview With AACR’s President-Elect

April 22, 2015

In this interview with ONCOLOGY Editor-in-Chief Nancy Davidson, MD, we dive into the “gray area” of breast biopsies and how the oncology community can meet this challenge. Dr. Davidson, AACR’s president-elect, also discusses the changes she has seen during her career with regard to how cancer patients are treated and looks forward during this optimistic time in treatment and research.

Adjuvant Endocrine Therapy for Breast Cancer: How Long Is Long Enough?

December 15, 2013

New evidence now supports improved recurrence and breast cancer mortality outcomes with continued tamoxifen for up to 10 years in women of any age, and such long-duration therapy is especially important for women who remain premenopausal after their first 5 years of tamoxifen.

Fifteen Years of Anti-HER2 Therapy

March 15, 2013

Last month brought the accelerated approval by the US Food and Drug Administration (FDA) of a fourth agent targeting the human epidermal growth factor receptor 2 (HER2) oncogene product: TDM-1 (Kadcyla), a conjugate of trastuzumab and a cytotoxic, emtansine.

25 Years Later: Endangered Species or Successful Evolution?

December 16, 2011

While ONCOLOGY has continued to evolve along with the field of oncology-for example, it now addresses critical issues of science and socioeconomics-it has remained true to the founding principles. Perhaps largely for this reason, the journal continues to be widely read across the entire oncology community.

HER2-Targeted Therapies: How Far We've Come

May 01, 2011

In 2004, Dr. Leisha Emens and I reviewed the use of trastuzumab (Herceptin), the monoclonal antibody directed against the HER2 protein, in the treatment of breast cancer.

Retrospective on the Last Quarter-Century in Medical Oncology

April 30, 2011

I began practice as a medical oncologist in 1986, and like the journal ONCOLOGY, I am celebrating my 25th year in the field.

Tracking 35 Years of Progress Against Breast Cancer

May 02, 2008

In this issue of ONCOLOGY we honor and celebrate the career and contributions of Martin D. Abeloff, MD, who died last year. Marty saw his first patient with breast cancer in 1972 and cared for his last such patient shortly before his death in 2007.